TY - BOOK ID - 138842904 TI - Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer AU - Ferroni, Patrizia AU - Roselli, Mario AU - Guadagni, Fiorella PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - multiple myeloma KW - venous thromboembolism KW - risk assessment models KW - thromboprophylaxis KW - direct oral anticoagulants KW - cancer-associated venous thromboembolism KW - thrombosis KW - pulmonary embolism KW - neoplasms KW - anticoagulants KW - coumarins KW - low molecular weight heparins KW - cancer KW - endogenous heparin KW - heparanase KW - heparan sulfate KW - hospice KW - palliative care units KW - low molecular weight heparin KW - deep vein thrombosis KW - cancer associated thrombosis KW - VTE KW - malignancy KW - direct oral anticoagulant KW - pancreatic cancer KW - low-molecular weight heparin KW - survival KW - coagulation activation KW - locally advanced breast cancer KW - prognostic model KW - pCR KW - treatment KW - prophylaxis KW - DOAC KW - simultaneous care KW - integrated care KW - lymphoma KW - Non-Hodgkin lymphoma KW - Hodgkin lymphoma KW - risk factors KW - molecular subtype KW - arterial thrombosis KW - ALK KW - ROS1 KW - KRAS KW - chemotherapy KW - low-molecular-weight heparin (LMWH) KW - VKA KW - UFH KW - DOACs KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:138842904 AB - Thromboembolism is a compelling challenge in cancer care because of its life-threatening nature as well as its impact on specific treatments. Current guidelines do not generally recommend antithrombotic prophylaxis, except in selected categories of patients at high risk of thrombosis. Accordingly, several clinical decision models have been developed to guide the oncologist in thromboembolic risk assessment and targeted prophylaxis. Low-molecular-weight heparins (LMWH) are currently considered as the standard approach in clinical practice guidelines, but recent randomized controlled trials (RCT) indicate that direct oral anticoagulants (DOACs) are effective for the treatment/prophylaxis of cancer-associated thromboembolism. However, many unanswered questions remain on the efficacy and safety of anticoagulants in selected cancer subgroups, and in primary and secondary prevention settings, where anticoagulation needs to be balanced on the risk of bleeding complications. Presently, patient selection remains the main challenge. Improvement in existing VTE risk models or the construction of alternative risk assessment tools are needed in order to ameliorate the risk stratification of cancer patients. This reprint will cover the current clinical evidence supporting the standard of care and emerging treatment/prophylactic options for cancer-associated thromboembolism during both active treatment and simultaneous/palliative care. Tailored approaches based on the use of individualized factors to stratify the thrombotic/bleeding risk in each individual patient are discussed. ER -